Chemotherapy in biliary tract carcinomas: Results in India
4
Citation
15
Reference
10
Related Paper
Keywords:
Carboplatin
Carboplatin
Cite
Citations (69)
OBJECTIVE: To explore the clinical effect of gemcitabine compared with carboplatin treatment in advanced non-small cell lung cancer.METHODS: Totally 98 cases with advanced non-small cell lung cancer were randomly divided into group A(gemcitabine compared with carboplatin) and group B(gemcitabine compared with cisplatin).Group A received gemcitabine of 1 000 mg/m2 on day 1 and 8,and carboplatin of AUC 5 on day 1.Group B were given cisplatin 80 mg/m2 on d1 and 2 based on gemcitabine treatment.Twenty-one days were for a cycle and all the patients received 2 cycles of treatments.Effective rate of treatment,1 year survival rate,adverse reaction rate and life quantity were compared between two groups.RESULTS: Effective rates of treatment were 39.7% and 40.0% in group A and group B respectively(P0.05);There were no significant difference of 1 year survival rate between two groups(52.1% vs 45.0%,P0.05);Grade Ⅲ~Ⅳgastrointestinal effect in group A were much less than that in group B(0 vs 12.5%,P0.05);LCSS scores after treatment in group A were superior to group B(P0.05).CONCLUSIONS: Gemcitabine compared with carboplatin or cisplatin treatment in advanced non-small cell lung cancer achieve the same effectiveness.Gemcitabine compared with carboplatin have less adverse reaction rate,and it is well-tolerated for patients.
Carboplatin
Group B
Group A
Cite
Citations (0)
The recurrence and prognosis of advanced cervical cancer patients is an unresolved medical need. To improve prognosis and bring new strategies to more curable stages of the disease, such as high-risk locally advanced disease patients and low metastatic or small volume disease patients. After culturing cervical cancer cells in vitro , they were treated with different concentrations of cisplatin and carboplatin drugs for 24, 48, and 72 hours respectively. Detected the inhibitory rate of different treatment groups on cervical cancer cells using CCK-8 detection, To observe live and dead cells through staining experiments. The results showed that different concentrations of cisplatin and carboplatin have significant inhibitory effects on cervical cancer cells. However, the inhibitory effect of cisplatin and carboplatin in the high concentration group on cervical cancer cells were significantly greater than that in the low concentration treatment group. The sensitivity of cervical cancer cells to cisplatin was similar with carboplatin, and the sensitivity to cisplatin was better than that of carboplatin. We believe that targeted therapy can be combined with chemotherapy drugs to enhance the anti-tumor effect of cisplatin. When the toxic side effects of cisplatin cannot be overcome, carboplatin can be considered to replace cisplatin in the treatment of cancer.
Carboplatin
Cite
Citations (0)
Carboplatin
Cite
Citations (1)
Carboplatin
Regimen
Cite
Citations (15)
12034 Background and Aim: Gemcitabine and capecitabine are antimetabolites that are effective in the pyrimidine pathway of the DNA synthesis. Capecitabine through a 3-step activation process is transformed to 5-FU in the tumor cell by thymidine phosphorilase. On the other hand, gemcitabine interacts with the enzymes thymidine kinase, tymidine phosphorilase ve ribonucloetide reductase. Our hypothesis is based on a possible synergistic blockade by concurrent administration of these two antimetabolites. Additionally, dipridamole is an inhibitor of the nucleoside transport; and that can prolong the accumulation of antimetabolites within the tumor cell. In this study, combinations of these drugs are tested on an animal model. Methods and Results: 80 male balb-c mice were inoculated dorsally with 0.1 cc Ehrlich ascites tumor, and 10 days later the animals were separated into 5 groups having a similar tumor load. The control group received no treatment, while in the gemcitabine arm the animals received 50 mg/d gemcitabine on day 1. In the capecitabine arm, the animals received 1mg/day capecitabine administered in drinking water on days 1–4. In the gemcitabine + capecitabine combination arm, the animals received both treatments. In the gemcitabine + capecitabine + dipridamole arm, in addition to both of the drugs, dipridamole was also given 2mg/day in drinking water on days 1–4. In the control group (n=16) median survival was 17 days, while it was 33 days in gemcitabine arm (n=11), 35 days in capecitabine arm (n=14), and 44 days in the gemcitabine + capecitabine combination arm (n=22) which was significantly higher (p<0.007). Dipridamole added to this combination (n=17) did not prolong survival any further. Conclusion: combination of gemcitabine with capecitabine suggests favorable results in an animal model. Testing of this combination in clinical trials seems to be justified. No significant financial relationships to disclose.
Cite
Citations (0)
Carboplatin
Cite
Citations (4)
Carboplatin
Peritoneal cavity
Cite
Citations (198)
Objective To observe the cytotoxicity of cisplatin combined with carboplatin on osteosarcoma cell line OS-732.Methods Using MTT assay,we obtained the mean IC50 of cisplatin and carboplatin for OS-732 cells.The OS-732 cells were incubated with following drugs for 48 or 72h: IC50 of cisplatin,IC50 of carboplatin,and 1/2 IC50 of cisplatin combined with 1/2 IC50 carboplatin.The cytotoxicity of each group was measured with MTT methods.Results The mean IC50 of cisplatin and carboplatin for osteosarcoma OS-732 cells for 48h was 7.6μg/ml and 199.0μg/ml respectively.The mean cytotoxicity index(CI) of 8.0μg/ml cisplatin, 200.0μg/ml carboplatin and 4.0μg/ml cisplatin+100.0μg/ml carboplatin for 48h were (54.7±5.3)%,(56.9±6.3)% and(57.5±5.7)% respectively(P0.05);and those for 72h were (65.7±4.5)%,(69.4±2.2)% and(68.4±3.6)% respectively,the cytotoxicity index increased significantly in groups containing carboplatin.Conclusion The combination of half dose cisplatin with carboplatin appears to be as active as cisplatin or carboplatin alone in full doses in treatment of osteosarcoma OS-732 cells in vitro.
Carboplatin
MTT assay
IC50
Cite
Citations (0)